GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Medically reviewed by Danielle Weiss, MD After losing extra pounds on Ozempic (semaglutide), some are finding themselves ...

The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Lexaria Bioscience (LEXX) has engaged a contract research organization to perform the world’s first-ever fluorescently tagged ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...